NCT05467319View on ClinicalTrials.gov

Ferric Derisomaltose/Iron Isomaltoside and Outcomes in the Recovery of Gynecologic Oncology ERAS

PHASE3UnknownINTERVENTIONAL

Enrollment

82

Participants

Timeline

Start Date

September 30, 2022

Primary Completion Date

September 30, 2023

Study Completion Date

December 31, 2023

Conditions

Gynecologic CancerAnemia, Iron DeficiencySurgery

Interventions

DRUG

Ferric Derisomaltose Injection

1000mg of ferric derisomaltose in 100mL of normal saline by intravenous infusion

DRUG

Normal saline

100 mL of 0.9% normal saline (w/v) by intravenous infusion

Sponsors

Collaborators (1)

Pharmacosmos A/S

All Listed Sponsors

collaborator

Pharmacosmos A/S

INDUSTRY

lead

Alberta Health Services, Calgary

OTHER